The Medullary thyroid cancer drugs market overview: Medullary thyroid cancer is a rare type of thyroid cancer that develops from the parafollicular C cells of the thyroid gland which produce calcitonin. It accounts for about 3-4% of all thyroid cancers. Symptoms include a lump in the neck, difficulty swallowing, and coughing or voice changes. Treatment involves surgery to remove the thyroid followed by radiation therapy or targeted drug therapies.

The medullary thyroid cancer drugs market is estimated to be valued at USD 156 Mn in 2024 and is expected to reach USD 315 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031.



Key Takeaways


Key players: Key players operating in the medullary thyroid cancer drugs are Pfizer, Bayer, and Eli Lilly & Company.

Pfizer's Cabometyx was approved by the FDA for the treatment of patients with locally advanced or metastatic RET fusion-positive thyroid cancer in 2018.


Growing demand: There has been a rising prevalence of medullary thyroid cancer owing to genetic and environmental factors which is driving the demand for targeted drug therapies in the Medullary Thyroid Cancer Drugs Market.


Global expansion: Major players are focusing on expanding their production facilities and distribution networks across Asian and Latin American countries to tap the high growth opportunities in emerging markets.



Market key trends

One of the major trends in the medullary thyroid cancer drugs market is the development of targeted therapies. Several pharmaceutical companies are conducting extensive R&D for developing precision medicines that can selectively target genetic mutations such as RET genes in medullary thyroid cancer cells. This allows targeted drugs to destroy cancer cells more efficiently with lesser side effects compared to traditional chemotherapy. Some pipeline targeted drug candidates are LOXO-292 by Loxo Oncology and BLU-667 by Blueprint Medicines which are currently in Phase 1/2 clinical trials.



Porter's Analysis



 Threat of new entrants: The threat of new entrants into the medullary thyroid cancer drugs market is moderate as extensive R&D is required to bring new drugs to market and gain regulatory approval.

 Bargaining power of buyers: Individual consumers possess moderate bargaining power due to the prevalence of the disease and healthcare access. However, large pharmacy benefit managers have strong bargaining power due to drug formulary control.

Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients and finished drugs have moderate bargaining power due to specialized expertise required for production. Threat of new substitutes: The threat of new substitutes is moderate to high as ongoing research continues to explore alternative treatment approaches.

Competitive rivalry: Competition is moderate to high among established pharmaceutical companies marketing drugs for medullary thyroid cancer treatment.



Geographical Regions



The medullary thyroid cancer drugs market in terms of value is currently concentrated in North America and Western Europe due to higher healthcare spending as well as more diagnosed and treated cases in these regions.



However, over the coming years the fastest growth in the medullary thyroid cancer drugs market is expected to occur in Asia Pacific excluding Japan as access to healthcare expands across countries such as China and India alongside growing awareness of diagnosis and treatment options. _

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)